University of Nevada at Las Vegas
Las Vegas, Nevada, 89154, United States
NCT Number: NCT05362968
Strawberries can be categorized as a functional food based on results from several clinical trials in improving cardiometabolic health beyond providing nutrition. Recent studies identify the role of strawberries in improving insulin resistance and risks of type 2 diabetes which urgently warrants further investigation, keeping in view the huge public health burden of diabetes in the US. In this study, the investigators propose to investigate the effects of a dietary achievable dose of strawberries on glycemic control, insulin resistance, and HbA1c (primary variables) and biomarkers of inflammation and endothelial function in a 28- week controlled crossover study.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1
Las Vegas, Nevada, 89154, United States
Strawberries are popularly consumed fruits in the US and are a rich source of several bioactive compounds with demonstrated health benefits in T2D and cardiovascular disease (CVD). Based on previously reported studies, strawberries have been shown to improve elevated lipid profiles/dyslipidemia, oxidative stress and inflammation in adults with the metabolic syndrome or prediabetes. In a recently reported study, strawberries at a dose of two-and-a-half servings per day for four weeks was shown to significantly reduce insulin resistance and serum adipokines in obese adults. These results conform to only a few reported trials using strawberries in adults with cardiometabolic risks. While these study findings are clinically meaningful, these warrant urgent investigation in trials of longer duration specifically targeting adults with impaired fasting glucose (vs. other features of the metabolic syndrome) as well as adults with diagnosed T2D with poor glycemic control despite taking medications. Furthermore, to the best of our knowledge, only one clinical trial has been reported on the role of strawberries in improving glycemic control, oxidative stress, and inflammation in adults with T2D. While these results are encouraging, they lack generalizability due to the short duration of the study (six weeks) that precludes accurate changes in glycated hemoglobin (HbA1c) as a stable biomarker of glucose control. Based on these gaps in the existing literature, the investigators will examine the effects of strawberry supplementation at a dose of 2.5 servings/day for 12 weeks on glycemic control and related cardiometabolic profiles in prediabetes in a randomized controlled crossover trial.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Whole strawberries are freeze-dried to form a powder with improved shelf life that will be used in this research study. Strawberry powder will be provided by the California Strawberry Commission (Watsonville, CA)
Other names: Freeze-dried strawberries
Time frame: 12 weeks
Blood glucose, insulin, glycated hemoglobin
Time frame: 12 weeks
Blood total and LDL cholesterol
Time frame: 12 weeks
cytokines C-reactive protein adhesion molecules
Time frame: 12 weeks
adiponectin, leptin
Time frame: 12 weeks
Serum measures of antioxidants
University of Nevada, Las Vegas
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06268990
Body Weight, Diabetes
Graz, Austria
View Trial DetailsNCT06350604
Behavior, Cardiovascular Diseases
Glassboro, New Jersey, United States
View Trial DetailsNCT06265337
Diabetes Mellitus, Endocrine System Diseases
Aarhus, Central Jutland, Denmark
View Trial DetailsNCT03543644
Body Weight, Cardiovascular Diseases
Toronto, Ontario, Canada
View Trial Details